RESOURCES

We strive to obtain the best data possible and offer to repeat the experiment, if necessary, to remedy errors or other observed anomalies.  

We provide reliable data for each project and demonstrate ethics, integrity and quality in everything we do for our clients and collaborators.  

We embrace diversity and foster an environment where we can all work together at our full potential. 

We carefully listen to our clients’ requirements and strictly follow the timeline.  

We explore new solutions for efficiency and quality.

We are proud of our work and desire to achieve scientific excellence and success.   

We ensure accurate and high-quality results by strictly adhering to our standardized workflows. 

We harness the power of our state-of-the-art technology to deliver unparalleled and all-encompassing solutions.  

We adhere to the highest ethical standards while maintaining flexibility in order to deliver exceptional services. 

We move together with speed and quality because clients and patients are waiting.  

We aim to make work processes and projects simpler and easier. 

We are open to all communications to ensure transparent partnership. 

 Genes and proteins play a crucial role in the regulation of cellular growth and signal transduction, rendering them potential targets or stratification markers for novel therapeutics. The main challenge lies in acquiring an adequate quantity of samples, such as cells or tissues, to analyze multiple biomolecules - particularly proteins that are traditionally investigated using techniques like LC-MS/MS, Western blot, IHC, or flow cytometry with substantial input amounts. At PicoImmune, our cutting-edge platforms empower us to evaluate the abundance and expression patterns of diverse DNAs, RNAs, and proteins even with minute samples (as few as 1-100 cells or 1 μl of plasma or serum). 

Protein and gene expression patterns and levels, including activation or inhibition of signaling pathways, and post-translational modifications, can significantly change following surgical resection or animal sacrifice at the end of studies. Results and read-outs from such samples are often misleading, as they might not accurately reflect molecular realities of drug effects within the human or animal body. Using our technology and standardized protocols for controlled and rapid tissue processing, we acquire minute samples in a minimally invasive way from patients or live animals and monitor real-time efficacy of novel therapies before, during, and after drug administration. Thus, we obtain more reliable and valuable information for gene and protein changes to support rational design of dosing strategies and evaluation of efficacy of novel drugs.

Coordinated application of PK/PD offers an efficient and informative approach to preclinical and clinical drug development. In clinical studies, core or fine needle aspirate biopsies (FNAB) are used routinely for PK/PD evaluation. In preclinical studies, whole tumor samples are often collected for the same studies requiring the sacrifice of animals at each time point, resulting in a substantial number of animals being used. By utilizing our patented µ-biopsy sampling technique combined with sensitive assays, we can ascertain PK/PD responses accurately, capture transient changes in target proteins effectively, and enable longitudinal studies to evaluate protein alterations associated with the development of drug resistance without relying on large cohorts of animals.

Proteins, the targets of most drugs, are often studied through indirect DNA or RNA surrogates, since many proteins lack cost-effective assays for quantitation due to limit of sample size. Critical information, such as post-transcriptional regulation (including mRNA stability and posttranslational modifications), is also often missed. Common technologies require either high amount of input samples, prohibitively complex expertise and sophisticated instruments (such as LC-MS/MS), or both for direct protein biomarker discovery and screening efforts. We now offer unique, sensitive, and reliable assays for many signaling proteins and disease mediators while requiring minimal amount of sample.

Our validated assays for cytokine, chemokine, tumor suppressor, oncoprotein, and other signaling molecule panels can be multiplexed up to 150-plex without losing specificity or sensitivity.

Our diverse assays can meet clients' various needs: large or limited volume of sample; high or low multiplex; ultra or high sensitivity; single cell, protein, mRNA, or microRNA data.
We have a panel of ready-to-use tumor and primary cell lines, bioassays, and animal models to support your drug discovery and development, from preclinical to clinical studies. 

Our assays to test drug effects on protein expression can be both qualitative and quantitative. Unlike ELISA and FACS, our assays measure protein amount after separation based on MW/ size or pI/charge changes (such as phosphorylation). Unlike western blotting which is often inconsistent and semi-quantitative at best, we quantitate the absolute amount of a protein (as low as pM level) in minimal amount of samples.